JohnnyGreig Jefferies has initiated coverage of Sarepta Therapeutics ( NASDAQ: SRPT ) at buy saying its Duchenne muscular dystrophy franchise represents a $4B+ opportunity, as well as a strong pipeline and business development activities. The label expansion of Elevidys in June is a boon.
Back to Health Page
